<a href="https://laohu8.com/S/CVM">CEL-SCI Corp</a>oration Awaits Saudi Food and Drug Authority's Decision on Breakthrough Medicine Designation for Multikine in Saudi Arabia
CEL-SCI Corporation has announced that a Breakthrough Medicine Designation application has been filed with the Saudi Food and Drug Authority (SFDA) for its product, Multikine (Leukocyte Interleukin, Injection), in the Kingdom of Saudi Arabia. This application was submitted by Dallah Pharma, a subsidiary of Dallah Healthcare Company, one of Saudi Arabia's leading pharmaceutical and healthcare providers. CEL-SCI has entered into a Memorandum of Understanding (MOU) with Dallah Pharma for the commercialization of Multikine in Saudi Arabia, with a final partnership agreement anticipated in the third quarter of 2025. The SFDA is expected to respond to the application within approximately 60 days, which, if approved, would enable Multikine to be immediately available for patient access and reimbursement in the region.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-25-009966), on August 25, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.